Generic Auvelity Availability

Last updated on Dec 12, 2024.

Auvelity is a brand name of bupropion/dextromethorphan, approved by the FDA in the following formulation(s):

AUVELITY (bupropion hydrochloride; dextromethorphan hydrobromide - tablet, extended release;oral)

Manufacturer: AXSOME
Approval date: August 18, 2022
Strength(s): 105MG;45MG ^[RLD]

Has a generic version of Auvelity been approved?

No. There is currently no therapeutically equivalent version of Auvelity available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Auvelity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Bupropion as a modulator of drug activity
Patent 10,058,518
Issued: August 28, 2018
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,064,857
Issued: September 4, 2018
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 10,080,727
Issued: September 25, 2018
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 10,092,560
Issued: October 9, 2018
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Patent 10,092,561
Issued: October 9, 2018
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
Patent 10,105,327
Issued: October 23, 2018
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 10,105,361
Issued: October 23, 2018
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,251,879
Issued: April 9, 2019
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 10,463,634
Issued: November 5, 2019
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 10,512,643
Issued: December 24, 2019
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 10,548,857
Issued: February 4, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Patent 10,596,167
Issued: March 24, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,772,850
Issued: September 15, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,780,064
Issued: September 22, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- January 7, 2040
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 10,780,066
Issued: September 22, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 9, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 10,786,469
Issued: September 29, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 10,786,496
Issued: September 29, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Combination of dextromethorphan and bupropion for treating depression
Patent 10,799,497
Issued: October 13, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,806,710
Issued: October 20, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,864,209
Issued: December 15, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,874,663
Issued: December 29, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,874,664
Issued: December 29, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,874,665
Issued: December 29, 2020
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 10,881,624
Issued: January 5, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,881,657
Issued: January 5, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,894,046
Issued: January 19, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,894,047
Issued: January 19, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,898,453
Issued: January 26, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,925,842
Issued: February 23, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- January 7, 2040
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,933,034
Issued: March 2, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 10,940,124
Patent expiration dates:
- January 7, 2040
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,945,973
Issued: March 16, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,966,941
Issued: April 6, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLP
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,966,942
Issued: April 6, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- January 7, 2040
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 10,966,974
Issued: April 6, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,020,389
Issued: June 1, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,058,648
Issued: July 13, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): Antecip Bioventures II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,090,300
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,096,937
Issued: August 24, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,123,343
Issued: September 21, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,129,826
Issued: September 28, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): AXSOME THERAPEUTICS, INC.
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,141,388
Issued: October 12, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,141,416
Issued: October 12, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): Antecip Bioventures II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Method of decreasing the fluctuation index of dextromethorphan
Patent 11,147,808
Issued: October 19, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,185,515
Issued: November 30, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,191,739
Issued: December 7, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  ✓
  Drug product
Bupropion as a modulator of drug activity
Patent 11,197,839
Issued: December 14, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  ✓
  Drug product
Bupropion as a modulator of drug activity
Patent 11,207,281
Issued: December 28, 2021
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,213,521
Issued: January 4, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Combination of dextromethorphan and bupropion for treating depression
Patent 11,229,640
Issued: January 25, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,234,946
Issued: February 1, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,253,491
Issued: February 22, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,253,492
Issued: February 22, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,273,133
Issued: March 15, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, methods related to sustained release of dextromethorphan or improved therapeutic effects. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,273,134
Issued: March 15, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,285,118
Issued: March 29, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,285,146
Issued: March 29, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,291,638
Issued: April 5, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,291,665
Issued: April 5, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,298,351
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,298,352
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,311,534
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,344,544
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,357,744
Issued: June 14, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,364,233
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,382,874
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,419,867
Issued: August 23, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,426,370
Issued: August 30, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,426,401
Issued: August 30, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,433,067
Issued: September 6, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  ✓
  Drug product
Bupropion as a modulator of drug activity
Patent 11,439,636
Issued: September 13, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,478,468
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,497,721
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,510,918
Issued: November 29, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,517,542
Issued: December 6, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,517,543
Issued: December 6, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,524,007
Issued: December 13, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 11,524,008
Issued: December 13, 2022
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,534,414
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  ✓
  Drug product
Patent 11,541,021
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,541,048
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,596,627
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,617,728
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,617,747
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO INCREASE DEXTROMETHORPHAN PLASMA LEVELS
Patent 11,717,518
Patent expiration dates:
- January 20, 2043
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,730,706
Patent expiration dates:
- January 23, 2043
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,752,144
Patent expiration dates:
- February 23, 2043
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,779,579
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,839,612
Patent expiration dates:
- March 2, 2043
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,844,797
Patent expiration dates:
- April 20, 2043
  ✓
  Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER BY ADMINISTERING DEXTROMETHORPHAN AND BUPROPION TO A SUBJECT HAVING MODERATE HEPATIC IMPAIRMENT
Patent 11,883,373
Patent expiration dates:
- January 23, 2043
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,896,563
Patent expiration dates:
- December 1, 2041
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,925,636
Patent expiration dates:
- January 20, 2043
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,969,421
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 11,986,444
Patent expiration dates:
- February 15, 2043
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 12,036,191
Patent expiration dates:
- February 15, 2043
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 12,042,473
Patent expiration dates:
- February 23, 2043
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 12,109,178
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Patent 12,146,889
Patent expiration dates:
- February 23, 2043
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods comprising tilidine or related compounds and dextromethorphan
Patent 8,569,328
Issued: October 29, 2013
Inventor(s): Tabuteau Herriot
Assignee(s): Antecip Bioventures II LLC
Pain and/or neurological disorders may be treated by administering a therapeutically effective amount of dextromethorphan and a therapeutically effective amount of a compound such as tilidine that inhibits the cytochrome P450 isozyme CYP2D6, to a person in need thereof. The two compounds may be administered separately, or in a single dosage form or composition as described herein.
Patent expiration dates:
- October 29, 2033
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
  ✓
  Drug product
Bupropion as a modulator of drug activity
Patent 9,168,234
Issued: October 27, 2015
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
Patent 9,198,905
Issued: December 1, 2015
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods of decreasing dextrorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Patent 9,205,083
Issued: December 8, 2015
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods of improving the efficacy of dextromethorphan, or providing beneficial pharmacokinetic effects to dextromethorphan, comprising co-administering erythrohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Patent 9,238,032
Issued: January 19, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 9,278,095
Issued: March 8, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects
Patent 9,314,462
Issued: April 19, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods of increasing dextromethorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,370,513
Issued: June 21, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods of increasing the metabolic lifetime of dextromethorphan administering threohydroxybupropion or bupropion to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and threohydroxybupropion or bupropion are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan
Patent 9,375,429
Issued: June 28, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods of improving the efficacy of dextromethorphan, or providing beneficial pharmacokinetic effects to dextromethorphan, comprising co-administering erythrohydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan and erythrohydroxybupropion or a prodrug of erythrohydroxybupropion are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Bupropion as a modulator of drug activity
Patent 9,408,815
Issued: August 9, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,421,176
Issued: August 23, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods of increasing dextromethorphan plasma levels comprising co-administering hydroxybupropion, or a prodrug thereof, and dextromethorphan to a human being in need of treatment with dextromethorphan. Dosage forms, drug delivery systems, and methods related to dextromethorphan and hydroxybupropion or a prodrug of bupropion are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,457,023
Issued: October 4, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
Patent 9,457,025
Issued: October 4, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,474,731
Issued: October 25, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Hydroxybupropion and related compounds as modulators of drug plasma levels
Patent 9,486,450
Issued: November 8, 2016
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering hydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and hydroxybupropion or a prodrug of hydroxybupropion are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,700,528
Issued: July 11, 2017
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,700,553
Issued: July 11, 2017
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,707,191
Issued: July 18, 2017
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,763,932
Issued: September 19, 2017
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,861,595
Issued: January 9, 2018
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,867,819
Issued: January 16, 2018
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
Patent 9,968,568
Issued: May 15, 2018
Inventor(s): Tabuteau Herriot
Assignee(s): ANTECIP BIOVENTURES II LLC
This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
Patent expiration dates:
- November 5, 2034
  ✓
  Patent use: DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- August 18, 2025 - NEW PRODUCT

More about Auvelity (bupropion / dextromethorphan)

Patient resources

Auvelity drug information

Professional resources

Related treatment guides

Major Depressive Disorder

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

8.6 / 10

129 Reviews

Images

Pill 45/105 is Auvelity bupropion hydrochloride 105 mg / dextromethorphan hydrobromide 45 mg — Auvelity bupropion hydrochloride 105 mg / dextromethorphan hydrobromide 45 mg (45/105)